Name | MBM-55 |
Description | MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. |
In vitro | MBM-55 (0.5-1 μM; 24 hours) induces G2/M phase arrest and accumulation of cells with >4N content in HCT-116 cells. MBM-55 (0.5-1 μM; 24 hours) causes cell apoptosis in a concentration-dependent manner in HCT-116 cells.MBM-55 inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC50s of 0.53, 0.84, 7.13 μM, respectively[1]. |
In vivo | In female BALB/c nu/nu mice bearing HCT-116 xenografts, MBM-55 (20 mg/kg; i.p.) exhibits good antitumor activity and a well-tolerated dose schedule. MBM-55 (1.0 mg/kg; i.v.) shows the CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 120 mg/mL (240.70 mM), Sonication is recommended.
|
Keywords | MBM-55 | Inhibitor | arrest | proliferation | antitumor | Apoptosis | cycle | cell | selectivity | inhibit | MBM 55 | Nek2 | MBM55 |
Inhibitors Related | Ribociclib | Cromolyn sodium | CHIR-99021 | sodium lauroyl-α-hydroxyethyl sulfonate | 4-Chloro-2'-bromoacetophenone | Artemisinin | CASIN | Imatinib | 2,3-Butanediol | Sodium Oxamate | Abemaciclib | Sodium salicylate |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |